Which has stronger earnings & valuation, ABSI or ERAS?

Absci has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Absci $2.80M 634.34 -$115.18M -$0.80 N/A Erasca N/A N/A -$124.55M -$0.95 N/A

Is ABSI or ERAS more profitable?

Erasca has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Erasca's return on equity of -38.43% beat Absci's return on equity. Company Net Margins Return on Equity Return on Assets Absci -7,756.38% -61.71% -54.52% Erasca N/A -38.43% -32.05%

Does the media favor ABSI or ERAS?

In the previous week, Absci had 1 more articles in the media than Erasca. MarketBeat recorded 8 mentions for Absci and 7 mentions for Erasca. Erasca's average media sentiment score of 0.85 beat Absci's score of 0.26 indicating that Erasca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Absci 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Erasca 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, PTCT or ABSI?

PTC Therapeutics has higher revenue and earnings than Absci. PTC Therapeutics is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PTC Therapeutics $1.73B 3.00 $682.64M -$0.58 N/A Absci $2.80M 634.34 -$115.18M -$0.80 N/A

Is PTCT or ABSI more profitable?

PTC Therapeutics has a net margin of -3.80% compared to Absci's net margin of -7,756.38%. Absci's return on equity of -61.71% beat PTC Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PTC Therapeutics -3.80% -362.45% -1.32% Absci -7,756.38% -61.71% -54.52%

Does the media prefer PTCT or ABSI?

In the previous week, PTC Therapeutics had 8 more articles in the media than Absci. MarketBeat recorded 16 mentions for PTC Therapeutics and 8 mentions for Absci. PTC Therapeutics' average media sentiment score of 0.46 beat Absci's score of 0.26 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Absci 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, GRFS or ABSI?

Grifols has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grifols $8.51B 0.58 $454.82M $0.19 37.89 Absci $2.80M 634.34 -$115.18M -$0.80 N/A

Is GRFS or ABSI more profitable?

Grifols has a net margin of 5.54% compared to Absci's net margin of -7,756.38%. Grifols' return on equity of 6.21% beat Absci's return on equity. Company Net Margins Return on Equity Return on Assets Grifols 5.54% 6.21% 2.39% Absci -7,756.38% -61.71% -54.52%

Does the media prefer GRFS or ABSI?

In the previous week, Absci had 4 more articles in the media than Grifols. MarketBeat recorded 8 mentions for Absci and 4 mentions for Grifols. Grifols' average media sentiment score of 0.56 beat Absci's score of 0.26 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Absci 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ABSI or CRSP more profitable?

CRISPR Therapeutics has a net margin of -3,368.72% compared to Absci's net margin of -7,756.38%. CRISPR Therapeutics' return on equity of -24.39% beat Absci's return on equity. Company Net Margins Return on Equity Return on Assets Absci -7,756.38% -61.71% -54.52% CRISPR Therapeutics -3,368.72% -24.39% -18.25%

Does the media refer more to ABSI or CRSP?

In the previous week, CRISPR Therapeutics had 9 more articles in the media than Absci. MarketBeat recorded 17 mentions for CRISPR Therapeutics and 8 mentions for Absci. CRISPR Therapeutics' average media sentiment score of 0.54 beat Absci's score of 0.26 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Absci 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CRISPR Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to EWTX or ABSI?

In the previous week, Edgewise Therapeutics had 5 more articles in the media than Absci. MarketBeat recorded 13 mentions for Edgewise Therapeutics and 8 mentions for Absci. Edgewise Therapeutics' average media sentiment score of 0.65 beat Absci's score of 0.26 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Absci 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Absci (ABSI) Competitors

$10.35 +0.61 (+6.26%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$10.56 +0.22 (+2.08%)

As of 04:43 AM Eastern

Compare

ABSI vs. ERAS, PTCT, GRFS, CRSP, and EWTX

Should you buy Absci stock or one of its competitors? Absci's main competitors and comparable companies include Erasca (ERAS), PTC Therapeutics (PTCT), Grifols (GRFS), CRISPR Therapeutics (CRSP), and Edgewise Therapeutics (EWTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Absci compare to Erasca?

Absci (NASDAQ:ABSI) and Erasca (NASDAQ:ERAS) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

52.1% of Absci shares are owned by institutional investors. Comparatively, 67.8% of Erasca shares are owned by institutional investors. 10.5% of Absci shares are owned by company insiders. Comparatively, 14.2% of Erasca shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Absci has a beta of 2.42, suggesting that its share price is 142% more volatile than the broader market. Comparatively, Erasca has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market.

Absci presently has a consensus price target of $13.71, indicating a potential upside of 32.51%. Erasca has a consensus price target of $22.09, indicating a potential upside of 52.14%. Given Erasca's higher possible upside, analysts clearly believe Erasca is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Erasca has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Erasca's return on equity of -38.43% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Absci	-7,756.38%	-61.71%	-54.52%
Erasca	N/A	-38.43%	-32.05%

In the previous week, Absci had 1 more articles in the media than Erasca. MarketBeat recorded 8 mentions for Absci and 7 mentions for Erasca. Erasca's average media sentiment score of 0.85 beat Absci's score of 0.26 indicating that Erasca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Absci	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Erasca	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Absci has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Absci	$2.80M	634.34	-$115.18M	-$0.80	N/A
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A

Summary

Absci beats Erasca on 8 of the 15 factors compared between the two stocks.

How does Absci compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Absci (NASDAQ:ABSI) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

PTC Therapeutics has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Absci has a beta of 2.42, indicating that its share price is 142% more volatile than the broader market.

PTC Therapeutics currently has a consensus target price of $99.08, suggesting a potential upside of 59.09%. Absci has a consensus target price of $13.71, suggesting a potential upside of 32.51%. Given PTC Therapeutics' higher possible upside, equities research analysts plainly believe PTC Therapeutics is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Absci	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

PTC Therapeutics has higher revenue and earnings than Absci. PTC Therapeutics is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.00	$682.64M	-$0.58	N/A
Absci	$2.80M	634.34	-$115.18M	-$0.80	N/A

52.1% of Absci shares are owned by institutional investors. 5.3% of PTC Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Absci shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, PTC Therapeutics had 8 more articles in the media than Absci. MarketBeat recorded 16 mentions for PTC Therapeutics and 8 mentions for Absci. PTC Therapeutics' average media sentiment score of 0.46 beat Absci's score of 0.26 indicating that PTC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Absci	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PTC Therapeutics has a net margin of -3.80% compared to Absci's net margin of -7,756.38%. Absci's return on equity of -61.71% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	-362.45%	-1.32%
Absci	-7,756.38%	-61.71%	-54.52%

Summary

PTC Therapeutics beats Absci on 10 of the 17 factors compared between the two stocks.

How does Absci compare to Grifols?

Grifols (NASDAQ:GRFS) and Absci (NASDAQ:ABSI) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

In the previous week, Absci had 4 more articles in the media than Grifols. MarketBeat recorded 8 mentions for Absci and 4 mentions for Grifols. Grifols' average media sentiment score of 0.56 beat Absci's score of 0.26 indicating that Grifols is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Absci	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

52.1% of Absci shares are held by institutional investors. 0.2% of Grifols shares are held by insiders. Comparatively, 10.5% of Absci shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Grifols has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Absci has a beta of 2.42, indicating that its share price is 142% more volatile than the broader market.

Grifols has a net margin of 5.54% compared to Absci's net margin of -7,756.38%. Grifols' return on equity of 6.21% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Absci	-7,756.38%	-61.71%	-54.52%

Grifols has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.58	$454.82M	$0.19	37.89
Absci	$2.80M	634.34	-$115.18M	-$0.80	N/A

Grifols presently has a consensus target price of $10.00, suggesting a potential upside of 38.89%. Absci has a consensus target price of $13.71, suggesting a potential upside of 32.51%. Given Grifols' higher probable upside, research analysts clearly believe Grifols is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Absci	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Grifols beats Absci on 9 of the 16 factors compared between the two stocks.

How does Absci compare to CRISPR Therapeutics?

Absci (NASDAQ:ABSI) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

Absci has a beta of 2.42, indicating that its stock price is 142% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

In the previous week, CRISPR Therapeutics had 9 more articles in the media than Absci. MarketBeat recorded 17 mentions for CRISPR Therapeutics and 8 mentions for Absci. CRISPR Therapeutics' average media sentiment score of 0.54 beat Absci's score of 0.26 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Absci	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CRISPR Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

52.1% of Absci shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 10.5% of Absci shares are held by insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CRISPR Therapeutics has a net margin of -3,368.72% compared to Absci's net margin of -7,756.38%. CRISPR Therapeutics' return on equity of -24.39% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Absci	-7,756.38%	-61.71%	-54.52%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

Absci currently has a consensus target price of $13.71, suggesting a potential upside of 32.51%. CRISPR Therapeutics has a consensus target price of $67.94, suggesting a potential upside of 21.98%. Given Absci's stronger consensus rating and higher probable upside, equities research analysts clearly believe Absci is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.59

Absci has higher earnings, but lower revenue than CRISPR Therapeutics. Absci is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Absci	$2.80M	634.34	-$115.18M	-$0.80	N/A
CRISPR Therapeutics	$3.51M	1,534.37	-$581.60M	-$4.76	N/A

Summary

CRISPR Therapeutics beats Absci on 10 of the 16 factors compared between the two stocks.

How does Absci compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Absci (NASDAQ:ABSI) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

52.1% of Absci shares are owned by institutional investors. 21.3% of Edgewise Therapeutics shares are owned by insiders. Comparatively, 10.5% of Absci shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Edgewise Therapeutics currently has a consensus target price of $51.33, indicating a potential upside of 24.72%. Absci has a consensus target price of $13.71, indicating a potential upside of 32.51%. Given Absci's higher probable upside, analysts clearly believe Absci is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Absci	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Edgewise Therapeutics had 5 more articles in the media than Absci. MarketBeat recorded 13 mentions for Edgewise Therapeutics and 8 mentions for Absci. Edgewise Therapeutics' average media sentiment score of 0.65 beat Absci's score of 0.26 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Absci	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Edgewise Therapeutics has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Absci has a beta of 2.42, suggesting that its share price is 142% more volatile than the broader market.

Edgewise Therapeutics has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Edgewise Therapeutics' return on equity of -39.01% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Absci	-7,756.38%	-61.71%	-54.52%

Absci has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Absci	$2.80M	634.34	-$115.18M	-$0.80	N/A

Summary

Edgewise Therapeutics and Absci tied by winning 8 of the 16 factors compared between the two stocks.

Get Absci News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABSI vs. The Competition

Export

Metric	Absci	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.84B	$3.98B	$7.32B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-12.94	14.00	274.39	25.76
Price / Sales	634.34	1,343.31	688.88	106.88
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	8.21	15.32	10.47	6.34
Net Income	-$115.18M	-$22.82M	$3.49B	$360.00M
7 Day Performance	7.25%	-1.92%	-0.91%	-0.16%
1 Month Performance	7.48%	-8.09%	-4.21%	-4.08%
1 Year Performance	290.57%	32.14%	16.39%	5.97%

Absci Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABSI Absci	2.6805 of 5 stars	$10.35 +6.3%	$13.71 +32.5%	+315.7%	$1.84B	$2.80M	N/A	140	Analyst Forecast
ERAS Erasca	2.5195 of 5 stars	$16.16 +1.8%	$22.09 +36.7%	+660.2%	$5.55B	N/A	N/A	103
PTCT PTC Therapeutics	3.6416 of 5 stars	$66.48 +0.6%	$98.50 +48.2%	+4.7%	$5.51B	$1.73B	N/A	991	Analyst Forecast
GRFS Grifols	4.761 of 5 stars	$7.48 -0.9%	$10.00 +33.7%	-27.0%	$5.14B	$8.51B	39.37	25,247	News Coverage
CRSP CRISPR Therapeutics	2.6449 of 5 stars	$52.96 +2.4%	$68.06 +28.5%	-8.8%	$5.00B	$3.51M	N/A	393	Trending News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABSI) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Absci (ABSI) Competitors

ABSI vs. ERAS, PTCT, GRFS, CRSP, and EWTX

How does Absci compare to Erasca?

Summary

How does Absci compare to PTC Therapeutics?

Summary

How does Absci compare to Grifols?

Summary

How does Absci compare to CRISPR Therapeutics?

Summary

How does Absci compare to Edgewise Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABSI vs. The Competition

Absci Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Absci (ABSI) Competitors

ABSI vs. ERAS, PTCT, GRFS, CRSP, and EWTX

How does Absci compare to Erasca?

Do insiders and institutionals believe in ABSI or ERAS?

Which has more risk and volatility, ABSI or ERAS?

Do analysts recommend ABSI or ERAS?

Is ABSI or ERAS more profitable?

Does the media favor ABSI or ERAS?

Which has stronger earnings & valuation, ABSI or ERAS?

Summary

How does Absci compare to PTC Therapeutics?

Which has more risk & volatility, PTCT or ABSI?

Do analysts recommend PTCT or ABSI?

Which has stronger earnings & valuation, PTCT or ABSI?

Do insiders & institutionals hold more shares of PTCT or ABSI?

Does the media prefer PTCT or ABSI?

Is PTCT or ABSI more profitable?

Summary

How does Absci compare to Grifols?

Does the media prefer GRFS or ABSI?

Do insiders and institutionals hold more shares of GRFS or ABSI?

Which has more volatility & risk, GRFS or ABSI?

Is GRFS or ABSI more profitable?

Which has better valuation & earnings, GRFS or ABSI?

Do analysts recommend GRFS or ABSI?

Summary

How does Absci compare to CRISPR Therapeutics?

Which has more volatility and risk, ABSI or CRSP?

Does the media refer more to ABSI or CRSP?

Do institutionals and insiders have more ownership in ABSI or CRSP?

Is ABSI or CRSP more profitable?

Do analysts rate ABSI or CRSP?

Which has stronger valuation & earnings, ABSI or CRSP?

Summary

How does Absci compare to Edgewise Therapeutics?

Do institutionals and insiders hold more shares of EWTX or ABSI?

Do analysts rate EWTX or ABSI?

Does the media refer more to EWTX or ABSI?

Which has more volatility and risk, EWTX or ABSI?

Is EWTX or ABSI more profitable?

Which has stronger valuation & earnings, EWTX or ABSI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABSI vs. The Competition

Absci Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools